Your browser doesn't support javascript.
loading
Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma
Romero-Laorden, N; Doger, B; Hernandez, M; Hernandez, C; Rodriguez-Moreno, JF; Garcia-Donas, J.
Afiliação
  • Romero-Laorden, N; Hospital Universitario HM Sanchinarro. Clara Campal Comprehensive Medical Center. Division of Medical Oncology. Madrid. Spain
  • Doger, B; Hospital Universitario Infanta Sofía. Division of Medical Oncology. Madrid. Spain
  • Hernandez, M; Hospital José Molina Orosa. Division of Medical Oncology. Lanzarote. Spain
  • Hernandez, C; Hospital Universitario HM Sanchinarro. Clara Campal Comprehensive Medical Center. Division of Medical Oncology. Madrid. Spain
  • Rodriguez-Moreno, JF; Hospital Universitario HM Sanchinarro. Clara Campal Comprehensive Medical Center. Division of Medical Oncology. Madrid. Spain
  • Garcia-Donas, J; Hospital Universitario HM Sanchinarro. Clara Campal Comprehensive Medical Center. Division of Medical Oncology. Madrid. Spain
Clin. transl. oncol. (Print) ; 18(1): 1-8, ene. 2016.
Artigo em Inglês | IBECS | ID: ibc-148045
Biblioteca responsável: ES1.1
Localização: BNCS
ABSTRACT
Antiangiogenic therapy is currently considered as the cornerstone of treatment in metastatic kidney cancer. A monoclonal antibody against the vascular endothelial growth factor (VEGF) and several tyrosine kinase inhibitors targeting the VEGF receptors demonstrated, 7 years ago, to deeply impact the outcome of this tumor and became a model of integration of molecular knowledge into clinical practice. Unfortunately, no further improvement in survival has been made and 20-25 % of cases remain primary refractory to these drugs, with an overall dismal prognosis. Since biomarker predictors of activity are lacking, their development could highly help in the process of making clinical decisions when choosing the best option for every patient or prompting the inclusion in clinical trials. This unmet medical need could become even more relevant if new immunotherapy confirms its initial promising results in this pathology. In this article, we provide an insight of current state of the art regarding the prediction of antiangiogenic efficacy in kidney cancer and propose new strategies for the implementation of such markers in clinical practice (AU)
RESUMEN
No disponible
Assuntos
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Terapêutica / Proteínas Tirosina Quinases / Carcinoma de Células Renais / Biomarcadores / Inibidores da Angiogênese / Tomada de Decisões / Fator A de Crescimento do Endotélio Vascular Tipo de estudo: Estudo diagnóstico / Estudo prognóstico / Fatores de risco Limite: Feminino / Humanos / Masculino Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2016 Tipo de documento: Artigo Instituição/País de afiliação: Hospital José Molina Orosa/Spain / Hospital Universitario HM Sanchinarro/Spain / Hospital Universitario Infanta Sofía/Spain
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Terapêutica / Proteínas Tirosina Quinases / Carcinoma de Células Renais / Biomarcadores / Inibidores da Angiogênese / Tomada de Decisões / Fator A de Crescimento do Endotélio Vascular Tipo de estudo: Estudo diagnóstico / Estudo prognóstico / Fatores de risco Limite: Feminino / Humanos / Masculino Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2016 Tipo de documento: Artigo Instituição/País de afiliação: Hospital José Molina Orosa/Spain / Hospital Universitario HM Sanchinarro/Spain / Hospital Universitario Infanta Sofía/Spain
...